Among the Nation’s Best
For the past five years, survival outcomes for patients receiving allogeneic sibling and unrelated donor transplants through our Blood & Marrow Transplantation (BMT) Center have been significantly better than would be expected in the types of patients we treat. Data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) showed that Roswell Park’s patient outcomes were better than what would be expected based on patient age, other existing health problems, whether or not the patient was in remission at the time of transplant, and how closely the patient was matched to the donor.
Roswell Park is among the 15 of 167 U.S. transplant centers who have achieved this distinction as reported to the CIBMTR.
BMT Outcomes for Multiple Myeloma
Between 2007-2013, Roswell Park's BMT Center performed 112 first auto peripheral blood stem cell transplants (PBSCTs) with melphalan 200mg/m2. All 112 patients (100 percent) were alive 100 days after PBSCT, and 94 percent were alive one year after PBSCT.